Nanobiotix reports ‘proof of concept’ for nanoparticles in
treating brain cancer
23 April 2009
Nanomedicine company Nanobiotix has announced that an independent
preclinical study has validated the applicability of using its
nanoparticles — nanoPDT — to treat glioblastoma multiforme, one of the
most prevalent brain tumours.
Nanobiotix expects to attract corporate partners for the development
of nanoPDT as the Company focuses development efforts on its nanoXray
Co-funded by Nanobiotix and Cancéropôle Lyon Auvergne Rhône-Alpes
(‘CLARA’), the ‘proof-of-concept’ preclinical study was conducted by the
French National Institute for Health and Medical Research (‘INSERM’)
under principal investigator and neuro-oncologist Prof. and Med. dr.
Laurent Lévy, PhD, President and CEO of Nanobiotix and Co-President
of the French Technology Platform on Nanotechnology (FTPN), said, "Our
nanotechnology is designed to allow for the precise destruction of
cancer cells via the controlled application of an outside-the-body
energy source — in this case, a laser beam.
"Of course, there is much more work to be done, but we are extremely
encouraged by these preclinical findings, which dramatically demonstrate
the therapeutic effect of nanoparticles on glioblastoma and open the
possibility of a new weapon with which neuro-oncologists might fight
this difficult-to-treat tumour."
"The nanoPDT particles allow for the controlled generation of
physical reactions in targeted cells when triggered by the application
of an external energy source — a laser beam in this case. This may have
significant ramifications for cancer therapy in the not-too-distant
future,” added Paras N Prasad, PhD, one of the world’s leading
authorities on nanotechnology and one of the inventors of the Nanobiotix
Dr Prasad is a co-founder of Nanobiotix and Executive Director of the
Institute for Lasers, Photonics and Biophotonics at SUNY (Buffalo, US).
Bookmark this page